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The aim of immunosuppressive treatment of Grave’s
orbitopathy (GO) is to limit acute inflammation and con-
gestion of orbital tissues. Application of intra-venous glu-
cocorticoid (GCS) pulses is presently the treatment of
choice in active (CAS≥3/7), moderate-to-severe, and
severe GO. Randomised trials (RTC) have proved this
treatment to be more efficient than oral glucocorticoid
therapy. The response rate of this regimen is about 80%.
However, exact schedules of GCS treatment have not yet
been uniquely established and depend on the experience
acquired in different centres.
According to the EUGOGO (2008) Consensus, to avoid
acute liver damage, the total GCS dose should not exceed
8.0g in a single therapy cycle. Typically, in current sche-
dules, the applied CGS dose per pulse per week is limited
and the duration of therapy extended to 12 weeks to deli-
ver a total methylprednisolone dose of 4.5g. While this
may not always be the optimum dose, according to the
EUGUGU (2012) randomised trial of the efficacy and
safety of three different cumulative doses of intravenous
methylprednisolone (2.5; 5.0 or 7.5 g) for moderate to
severe and active GO, the dose of 7.5g was found to be
most effective. It appears therefore that intravenous
methylprednisolone treatment should be individualised
depending on the severity of GO (NOSPECS criteria) and
inflammation activity (CAS).
Orbital radiotherapy (RT) is less efficient in GO than in
GCS but, as based on rather scarce RCT reports, oral glu-
cocorticoid therapy combined with orbital radiotherapy
(20 Gy) appears to give better results than GCS alone
(efficacy of about 70-80%). Again, no single schedule of
combined GCS and RT has been established since no
randomised trials with intravenous glucocorticoid have
been conducted.
According to our experience of over a decade, GCS
pulse treatment followed by orbital irradiation improves
the treatment outcome, especially in patients with eye
muscle involvement, and reduces the frequency of
recurrence.
Restoring permanent euthyroidism is very important in
GO therapy. Radioiodine therapy should be considered in
patients with poorly controlled hyperthyroidism. Oral
GCS should be given to patients with risk factors or
active GO for radioiodine use, however no randomised
clinical trials have been performed to ascertain the opti-
mum GCS dose. According to our experience, ablative
131-I doses should be applied to efficiently control thyr-
oid function.
Radioiodine therapy can also take place while GCS
pulses are delivered, with RT supplied after completion
of methylprednisolone treatment. Randomised prospec-
tive trials are also necessary to assess the efficacy of these
treatment schedules.
In our investigations, we have found that the group of
patients who, following 131-I therapy, have reported to
our Department with severe GO, demonstrated signifi-
cantly higher levels of TSH and TRAb, than patients trea-
ted with anti-thyroid drugs. It is for this reason that to
avoid hypothyroidism, early control of Grave’s disease
patients treated with 131-I is essential.
According to the Amsterdam Declaration, detailed
knowledge of the course of disease, avoiding recurrence of
hyperthyroidism, and prompt qualification for well-selected
treatment by an experienced endocrinologist- ophthalmol-
ogist team will improve the efficacy of GO treatment and
protect the patient against severe orbitopathy.
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